Ultragenyx Pharmaceutical announced that the Phase 3 study of Crysvita met its primary endpoint demonstrating that Crysvita was superior to oral phosphate and active vitamin D in improving rickets in children with X-linked hypophosphatemia, or XLH, after 40 weeks of treatment. The study also showed improvement in important metabolic and functional measures with Crysvita treatment, and a safety profile similar to that observed in other Crysvita pediatric XLH studies. Crysvita is an antibody that blocks fibroblast growth factor 23, or FGF23, a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.